BioSpace News Archive

Significant milestone toward the commercialization of eptinezumab, the first quarterly infusion therapy for migraine prevention

DBV Technologies Announces Publication of Detailed Phase III Trial Results Evaluating Viaskin Peanut as a Novel Treatment for Peanut Allergy in The Journal of the American Medical Association

Karolinska Development’s portfolio company Modus Therapeutics announces that the first cohort has been successfully dosed in its

Planegg Medigene AG announced its participation at the following upcoming scientific conferences

One third of hypertrophic cardiomyopathy cases in Finland are caused by one of the four major mutations, a new study from the University of Eastern Finland and Kuopio University Hospital shows.

Microchip-based high-throughput screening system helps open innovation and creativity in life sciences.

Clinigen Group plc (AIM: CLIN, ‘Clinigen’), the global pharmaceutical and services company, has been granted by the Medicines and Healthcare products Regulatory Agency (MHRA), an additional indication for Glycopyrronium Bromide 1mg/5ml Oral Solution (‘Glyco’).

Modus Therapeutics AB, a company developing innovative treatments for patients with high unmet medical needs and a focus on sickle cell disease (SCD), announces that the first cohort has been successfully dosed in its Phase 1, Single Ascending Dose Study to Explore the Pharmacokinetics and Safety & Tolerability of Subcutaneous Sevuparin Injections in Healthy Volunteers (HV)

GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, announced that David Johnson, Ph.D., chief executive officer, will present at the 2019 Antibody Engineering & Therapeutics Asia Meeting.

Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced the publication of an important clinical study regarding its Vectra® test in Current Medical Research & Opinion.